Skye Bioscience Investor Presentation — March 2021

Document content

March 2021 • OTCQB: SKYE

Unlocking the Pharmaceutical

Potential of Cannabinoids Legal Disclaimer

skyebioscience.com •2This presentation contains “forward -looking statements”,

including statements regarding Skye Bioscience, Inc.and its

subsidiaries, within the meaning ofthe “safe harbor” provisions

ofthe Private Securities Litigation Reform Act of1995 .All the

statements inthis presentation, whether written ororal, that

refer toexpected oranticipated future actions and results of

Skye Bioscience are forward -looking statements .Inaddition,

any statements that refer toexpectations, projections, orother

characterizations of future events or circumstances are

forward -looking statements . These forward -looking

statements reflect our current projections and expectations

about future events asofthe date ofthis presentation .Skye

Bioscience cannot give any assurance that such forward -

looking statements will prove tobe correct .The reader is

cautioned not toplace undue reliance on these forward -

looking statements .

The information provided inthis presentation does not identify

orinclude any risk orexposures, ofSkye Bioscience that would

materially adversely affect the performance orrisk ofthe

company .For adescription ofthe risks and uncertainties

related tothe business ofSkye Bioscience, see our Annual

Report orForm 10-Kfiled with the Securities and Exchange

Commission and our subsequent periodic reports filed with the

Securities and Exchange Commission .Allinformation contained inthis presentation isprovided asof

the date ofthe presentation and issubject tochange without

notice .Neither Skye Bioscience, nor any other person

undertakes any obligation toupdate orrevise publicly any of

Preview truncated — download the full document for the complete content.